Solubility

Peptide solubility refers to the maximum stable concentration in a given solvent at defined temperature and pressure. It is a critical parameter for in vitro and in vivo research: an insoluble or partially aggregated peptide yields non-reproducible experimental results, biased dose-response curves, and a risk of occluding administration devices.

Physicochemical factors governing solubility are multiple. Primary sequence is the dominant determinant: a peptide rich in polar or charged amino acids (arginine, lysine, glutamate, aspartate, serine, threonine) is generally highly soluble in aqueous media, while a peptide rich in hydrophobic residues (valine, leucine, isoleucine, phenylalanine, tryptophan) or aromatic residues tends to aggregate through π-stacking or hydrophobic interactions. pH affects the protonation state of ionizable side chains: minimum solubility occurs at the isoelectric point (pI), where net charge is zero. Ionic strength, temperature, and presence of co-solvents (DMSO, DMF, acetonitrile, ethanol) also modulate solubility.

Secondary structure plays a non-negligible role: peptides prone to form intermolecular β-sheets (rich in valine/isoleucine, glutamine, aggregation hot-spots) easily precipitate as amyloid fibrils, even at moderate concentration. Predictive tools (TANGO, Zyggregator, PASTA, AggreScan) identify these risk regions before synthesis.

Common research solvents vary by application. Bacteriostatic water (water for injection plus 0.9 % benzyl alcohol) is the reference for hydrophilic, non-fragile peptides (BPC-157, TB-500, GHK-Cu, most GLP-1 analogs, GHRPs/GHRHs). For poorly soluble peptides, mixed solvents such as 10-30 % aqueous acetic acid, DMSO < 1 % final concentration, or phosphate buffer pH 7.4 are used. Hydrophobic cyclic or acylated peptides sometimes require surfactant formulations (polysorbate, cyclodextrin).

Solubility improvement strategies include adding polar terminal residues (poly-lysine, poly-glutamate, hydrophilic tags), PEGylation, glycosylation, substitution of hydrophobic amino acids with their hydrophilic analogs without loss of activity, and design of D-enantiomers or D-retro-inverso peptides that can show different solubility profiles. Pharmaceutically, poor solubility limits oral and topical bioavailability, and formulation (liposomes, nanoparticles, excipients) then becomes critical for clinical development.